In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists

European Journal of Clinical Pharmacology

Volumn 56, Issue 2, 2000, Pages 135-140

  Taavitsainen, P ^a   Kiukaanniemi, K ^a   Pelkonen, O ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

CYP; Inhibitory interactions; Sartans

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; EPROSARTAN; IRBESARTAN; LOSARTAN; VALSARTAN;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HUMAN; HYDROXYLATION; LIVER MICROSOME; PRIORITY JOURNAL;

ACRYLATES; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; LOSARTAN; MICROSOMES, LIVER; PROTEIN ISOFORMS; RECEPTORS, ANGIOTENSIN; TETRAZOLES; THIOPHENES; VALINE;

EID: 0034119823     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050731     Document Type: Article

References (28)

1. Aitio A (1978) A simple and sensitive assay of 7-hydroxycoumarin deethylation. Anal Biochem 85: 488-491
2. Boobis AR, Secardic D, Murray BP, Edwards RJ, Singleton AM, Rich KJ, Murray S, Delatorre R, Segura J, Pelkonen O, Pasanen M, Kobayashi S, Zhiguang T, Davies DS (1990) Species variation in the response of the cytochrome P450-dependent monooxygenase system to inducers and inhibitors. Xenobiotica 20: 1139-1161
3. Bourrie M, Meunier V, Berger Y, Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277: 321-332
4. Burke MD, Prough RA, Mayer RT (1977) Characteristics of a microsomal cytochrome P-448-mediated reaction ethoxyresorufin O-deethylation. Drug Metab Dispos 5: 1-8
5. Gillis JC, Markham A (1997) Irbesartan. Drugs 54: 885-902
6. Goa KL, Wagstaff AJ (1996) Losartan potassium. Drugs 51: 820-845
7. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752
8. Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC, Etheredge R, Jorkasky DK (1997) Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 62: 417-425
9. Kerry NL, Somogyi AA, Bochner F, Mikus G (1994) The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol 38: 243-248
10. Knodell RG, Hall SD, Wilkinson GR, Guengerich FP (1987) Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther 241: 1112-1119
11. Kronbach T, Mathys D, Gut J, Catin T, Meyer UA (1987) High-performance liquid Chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162: 24-32
12. Markham A, Goa KL (1997) Valsartan. Drugs 54: 299-311
13. McClellan KJ, Balfour JA (1998) Eprosartan. Drugs 55: 713-718
14. McClellan KJ, Goa KL (1998) Candesartan cilexetil. Drugs 56: 847-869
15. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ (1995) Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 5: 143-150
16. Park YH, Kullberg MP, Hinsvark ON (1984) Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. J Pharm Sci 73: 24-29
17. Pelkonen O, Puurunen J (1980) The effect of cimetidine on in vitro and in vivo microsomal drug metabolism in the rat. Biochem Pharmacol 29: 3075-3080
18. Pelkonen O, Kaltiala EH, Larmi TKI, Kärki NT (1974) Cytochrome P-450-linked monooxygenase system and drug-induced spectral interactions in human liver microsomes. Chem Biol Interact 9: 205-216
19. Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28: 1203-1253
20. Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxocol 3: 566-573
21. Raunio H, Syngelmä T, Pasanen M, Juvonen R, Honkakoski P, Kairaluoma MA, Sotaniemi E, Lang MA, Pelkonen O (1988) Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat and mouse. Biochem Pharmacol 37: 3889-3895
22. Raunio H, Valtonen J, Honkakoski P, Lang MA, Ståhlberg M, Kairaluoma MA, Rautio A, Pasanen M, Pelkonen O (1990) Immunochemical detection of human liver cytochrome P450 forms related to phenobarbital-inducible forms in the mouse. Biochem Pharmacol 40: 2503-2509
23. Somogyi A, Muirhead M (1984) Pharmacokinetic interactions of cimetidine. Clin Pharmacokinet 12: 321-366
24. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6: 341-349
25. Waxman DJ, Ko A, Walsh C (1983) Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J Biol Chem 258: 11 937-11 947
26. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzales FJ, Korzekwa K (1991) Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 290: 160-166
27. Williamson KM, Patterson JH, McQueen RH, Adams KF, Pieper JA (1998) Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 63: 316-323
28. Wrighton SA, Stevens JC, Becker GW, VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306: 240-245